Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Andrew E. Hendifar"'
Autor:
Eric, Van Cutsem, Margaret A, Tempero, Darren, Sigal, Do-Youn, Oh, Nicola, Fazio, Teresa, Macarulla, Erika, Hitre, Pascal, Hammel, Andrew E, Hendifar, Susan E, Bates, Chung-Pin, Li, Sunil R, Hingorani, Christelle, de la Fouchardiere, Anup, Kasi, Volker, Heinemann, Anthony, Maraveyas, Nathan, Bahary, Laura, Layos, Vaibhav, Sahai, Lei, Zheng, Jill, Lacy, Joon Oh, Park, Fabienne, Portales, Paul, Oberstein, Wilson, Wu, Dimitrios, Chondros, Andrea J, Bullock
Publikováno v:
Scientia
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa8b97ebf9ba99cec6f3515308b207bd
https://hdl.handle.net/11351/6453
https://hdl.handle.net/11351/6453
Autor:
Hingorani SR; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Zheng L; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Bullock AJ; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Seery TE; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Harris WP; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Sigal DS; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Braiteh F; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Ritch PS; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Zalupski MM; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Bahary N; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Oberstein PE; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Wang-Gillam A; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Wu W; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Chondros D; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Jiang P; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Khelifa S; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Pu J; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Aldrich C; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ., Hendifar AE; Sunil R. Hingorani, Fred Hutchinson Cancer Research Center; William P. Harris, University of Washington, School of Medicine, Seattle, WA; Lei Zheng, Johns Hopkins University School of Medicine, Baltimore, MD; Andrea J. Bullock, Beth Israel Deaconess Medical Center, Boston, MA; Tara E. Seery, Chan Soon-Shiong Institute for Medicine, El Segundo; Darren S. Sigal, Scripps Cancer Center, La Jolla; Wilson Wu, Dimitrios Chondros, and Ping Jiang, Halozyme Therapeutics, San Diego; Andrew E. Hendifar, Cedars-Sinai Medical Center and Samuel Oschin Cancer Center, Los Angeles, CA; Fadi Braiteh, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Paul S. Ritch, Froedtert Hospital and Medical College of Wisconsin, Milwaukee, WI; Mark M. Zalupski, University of Michigan, Ann Arbor, MI; Nathan Bahary, University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA; Paul E. Oberstein, Columbia University Medical Center, New York, NY; Andrea Wang-Gillam, Washington University, St Louis, MO; and Sihem Khelifa, Jie Pu, and Carrie Aldrich, Ventana Medical Systems, Tucson, AZ.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Feb 01; Vol. 36 (4), pp. 359-366. Date of Electronic Publication: 2017 Dec 12.
Autor:
Chawla SP; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA. santchawla@sarcomaoncology.com., Cranmer LD; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Van Tine BA; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Reed DR; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Okuno SH; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Butrynski JE; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Adkins DR; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Hendifar AE; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Kroll S; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA., Ganjoo KN; Sant P. Chawla, Sarcoma Oncology Center, Santa Monica; Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles; Stew Kroll, Threshold Pharmaceuticals, South San Francisco; Kristen N. Ganjoo, Stanford University Medical Center, Stanford, CA; Lee D. Cranmer, University of Arizona Cancer Center, Tucson, AZ; Brian A. Van Tine and Douglas R. Adkins, Washington University in St Louis, St Louis, MO; Damon R. Reed, Moffitt Cancer Center and Research Institute, Tampa, FL; Scott H. Okuno, Mayo Clinic, Rochester, MN; and James E. Butrynski, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Oct 10; Vol. 32 (29), pp. 3299-306. Date of Electronic Publication: 2014 Sep 02.